SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

Starting soon · Phase 3

Conditions studied: Non-Small Cell Lung Cancer

In brief

This is a randomized, open-label, multicenter Phase III clinical trial, designed to evaluate the efficacy and safety of SYS6010 versus docetaxel in participants with Locally Advanced or Metastatic EGFR Wild-type Non-squamous Non-small Cell Lung Cancer who Have Failed Standard Therapy. The primary Objective is to evaluate the efficacy of SYS6010 versus docetaxel in participants with EGFR wild-type locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC). Secondary Objectives includes safety, quality of life, immunogenicity, biomarkers, and efficacy correlations of SYS6010 compared to docetaxel in the same patient population.

Key facts

Study ID

NCT07442565

Run by

CSPC Megalith Biopharmaceutical Co.,Ltd.

People needed

506

Starts

2026-03-10

Expected to finish

2031-05-30

Last updated by the study team

2026-03-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Voluntarily participate in this clinical study, understand the study procedures, and be able to sign the written ICF (Informed Consent Form); 2. Age ≥18 years, with no restriction on sex; 3. Patients with pathologically confirmed locally advanced or metastatic EGFR wild-type non-squamous non-small cell lung cancer (nsq-NSCLC). Stage IIIB or IIIC patients unsuitable for surgical resection or radical chemoradiotherapy, or Stage IV NSCLC patients. EGFR mutations (currently approved by regulatory authorities for targeted therapy) must be confirmed negative. If test results are unavailable, participants need to provide tumor tissue to undergo genetic testing.
• Meet either of the following requirements regarding prior treatment for locally advanced or metastatic EGFR wild-type nsq-NSCLC:
• Driver gene-negative population must have failed only immune therapy and platinum-based chemotherapy ± anti-angiogenic therapy (limited to first-line regimens approved by regulatory authorities).
• Other driver gene-positive populations must have received and failed only targeted therapy for the driver gene and platinum-based chemotherapy ± anti-angiogenic therapy (limited to first-line regimens approved by regulatory authorities).
• Have at least one measurable lesion confirmed by CT or MRI according to RECIST v1.1 criteria; 6. ECOG performance status score 0-1; 7. Expected survival ≥3 months as judged by the investigator. 8. Within 7 days before the first administration, the body organs and bone marrow function meet the requirements, defined as follows (Note: For hematological tests, participants must not have received blood component transfusion, G-CSF, TPO, TPO-RA, IL-11, or EPO within 2 weeks prior to randomization):
• ANC ≥1.5×10⁹/L
• Platelets (PLT) ≥100×10⁹/L
• Hemoglobin (HGB) ≥100 g/L
• Serum creatinine (Cr) ≤1.5×ULN AND creatinine clearance ≥50 mL/min (calculated by Cockcroft-Gault formula)
• Total bilirubin (TBIL): ≤1.5×ULN for patients without liver metastases; ≤3×ULN for patients with Gilbert's syndrome or liver metastases
• ALT/AST: ≤2.5×ULN for patients without liver metastases; ≤5×ULN for patients with liver metastases
• APTT and INR ≤1.5×ULN 9. Female participants of childbearing potential must have a negative pregnancy test within 7 days before randomization. All participants must agree to use effective contraception from the time of signing the ICF until 7 months after the last dose. During this period, female participants must not be breastfeeding, and male participants must refrain from sperm donation.

You may not qualify if…

• Histologically or cytologically confirmed small cell lung cancer, squamous cell carcinoma, neuroendocrine carcinoma, or sarcomatoid carcinoma
• Patients with: Leptomeningeal metastasis, brainstem metastasis, spinal cord metastasis and/or compression, or active CNS metastases.
• Exception: Supratentorial and/or cerebellar metastases (excluding midbrain, pons, or medulla) are allowed if: Received local therapy (e.g., radiation/surgery) Stable for ≥2 weeks before randomization (no new lesions/enlargement on imaging, stable/improved neurological symptoms). No corticosteroids or ≤10 mg prednisone (or equivalent) daily.
• Other malignancies within 3 years before randomization, except: Cured basal/squamous cell skin cancer, superficial bladder cancer, prostate/cervical carcinoma in situ.
• Known allergies: To any component of SYS6010 or humanized monoclonal antibodies. Contraindications/hypersensitivity to docetaxel.
• Residual toxicities from prior antitumor therapy > Grade 1 (per NCI-CTCAE v6.0), except: Grade 2 alopecia or other toxicities deemed non-risky by investigators.
• Prior treatment with topoisomerase I inhibitors (including ADCs).
• Inadequate washout periods:
• <!-- -->
• Major surgery (excluding biopsies) within 4 weeks before first dose.
• Last antitumor therapy before first dose:
• Chemotherapy/radical radiotherapy/targeted/immunotherapy: ≥4 weeks. Small-molecule targeted drugs/TCM with antitumor claims/palliative radiotherapy/local therapy: ≥2 weeks.
• Within 2 weeks before first dose: IV antibiotics/antifungals/antivirals for the purpose of anti-infective therapy; strong CYP3A4 inducers/inhibitors; OATP1B1/1B3 inhibitors.
• Investigational drugs/live vaccines within 4 weeks before first dose. 8. Severe cardiovascular diseases within 6 months before randomization, including: Clinically significant arrhythmias (e.g., ventricular arrhythmia, AV block ≥ Grade III); QTcF >470 ms (Fridericia's formula) Myocardial infarction, unstable angina, aortic dissection, angioplasty, CABG. Heart failure ≥ NYHA Class II or LVEF <50%. Stroke or Grade ≥3 cardiovascular events. Pulmonary embolism. 9. History of ILD/non-infectious pneumonitis requiring steroids; current ILD; or suspected ILD on imaging/pulmonary function tests (severe ventilation/diffusion impairment).
• Severe infections within 4 weeks before randomization (e.g., bacteremia, severe pneumonia, active TB); active infections requiring IV antibiotics within 2 weeks.
• History of ulcerative colitis or Crohn's disease. 12. Pleural/pericardial effusion requiring intervention within 2 weeks. 13. Active HBV/HCV infection: HBV: HBsAg+ and/or HBcAb+ with HBV DNA ≥10⁴ copies/mL (or ≥2000 IU/mL).
• HCV: HCV Ab+ with HCV RNA above detection limit. Note: Antiviral therapy (e.g., entecavir/tenofovir) is recommended for HBsAg+ patients before randomization.
• Immunodeficiency (HIV+, congenital/acquired immune disorders) or allogeneic transplant history.
• Other conditions deemed ineligible by investigators (e.g., uncontrolled psychiatric disorders, hypertension/diabetes).

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.